{"links":{"feed":"https://www.erudio.com/reports/sunray-02-nct06890598/feed.json","html":"https://www.erudio.com/reports/sunray-02-nct06890598","json":"https://www.erudio.com/reports/sunray-02-nct06890598.json","markdown":"https://www.erudio.com/reports/sunray-02-nct06890598.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"sunray-02-nct06890598"}},"request":"https://www.erudio.com/contact?report=sunray-02-nct06890598"},"offer":{"cited_clinicians":3,"cited_commentary_sources":7,"verified_hcp_statements":42,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":3},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"sunray-02-nct06890598"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=sunray-02-nct06890598","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/sunray-02-nct06890598","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 42 verified statements · 12 from 3 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-22T00:10:38.851872Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":7,"no_commentary_found":3},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Part A: Disease-Free Survival (DFS) by Investigator Assessment"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Part B: Progression-Free Survival (PFS) by BICR"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":1,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":1,"title":"Population and setting"},{"claim_count":2,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":4,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.interventions","source_count":3,"title":"Safety and tolerability"},{"claim_count":1,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":4,"title":"Earlier-phase efficacy and biomarker rationale"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":1,"title":"Regimen naming and cross-study interpretation"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":1,"title":"Individualized combination versus single-agent selection"}],"counts":{"beyond_population_findings":3,"beyond_population_statements":15,"cited_clinicians":3,"cited_clinicians_by_role":{"physician":1,"physician, Medical oncology":2},"cited_physicians":3,"cited_sources":8,"claims_by_expression_type":{"comparison":2,"interpretation":20,"opinion":6,"primary_context":3,"restatement":6,"uncertainty":3,"unspecified":2},"claims_by_kind":{"interpretation":2,"protocol_statement":3,"publication_statement":23,"source_observation":14},"clinician_statements":12,"evidence_units":32,"findings":4,"organisational_accounts":1,"people_cited":4,"people_identity_verified":3,"people_total":4,"screened_sources":29,"verified_claims":42},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":1},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":1,"passages":5,"sources":3,"sources_by_kind":{"commentary":2,"publication":1}},"title":"SUNRAY-02: what speakers say","evidence_line":"4 statements from 1 speaker in 3 sources"},{"cited_clinicians":1,"id":"F2","population":"beyond","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":2,"views":2},"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":1,"passages":3,"sources":2,"sources_by_kind":{"media":1,"publication":1}},"title":"Olomorasib with chemotherapy: a clinician weighs preliminary safety, noting cytopenias","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-3e33141bdebe1b077269"],"clause":"noting cytopenias","holders":1},"cited_claim_ids":["claim-3e33141bdebe1b077269","claim-9361a50f573489f51ea6"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"5 statements from 1 speaker in 2 sources, 1 of them a podcast or video","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “noting cytopenias”"},{"cited_clinicians":1,"id":"F3","population":"beyond","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":5,"views":3},"limitations":3,"links":{"context":5,"support":14},"ma_question":true,"named_voices":2,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"LOXO-RAS-20001: what speakers highlight in first-line PD-L1-high responses","title_holders":{"cited_claim_ids":["claim-05c5a78381e6274715b9","claim-c81ead16ddc0ed6f0492","claim-d536a4ed5a806ac60994","claim-e709a2af8f287cda100f"],"clinicians":false,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"9 statements from 2 speakers in 5 sources","holder_line":"2 of the 2 named speakers in this finding hold this view"},{"cited_clinicians":1,"id":"F4","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":1},"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"media":1}},"title":"Combinations: how a clinician weighs toxicity and single-agent options","title_holders":{"cited_claim_ids":["claim-b11e98f12fa69cad92e5","claim-2628585fc49136bd091a"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One X account highlights the move to earlier combination treatment"},{"id":"section-2","level":2,"title":"Beyond the trial population"},{"id":"section-3","level":3,"title":"One speaker finds a chemotherapy-containing combination feasible, with important qualifications"},{"id":"section-4","level":3,"title":"One physician’s enthusiasm rests on early-phase activity and a relative tolerability judgment"},{"id":"section-5","level":3,"title":"One speaker leaves patient selection and single-agent treatment open"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Part A: Disease-Free Survival (DFS) by Investigator Assessment"},{"findings":[],"id":"T2","label":"Primary endpoint: Part B: Progression-Free Survival (PFS) by BICR"},{"findings":[],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-22T00:10:38.851872Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-22T00:23:12Z","record_hash":"4c69b06454e78099b9bfa170d7b5d16942e756aab0e14d7070fa9d076fdc780c","release_hash":"6b191e5d20cfea3f3ee70c88858755234cd4039d2df4fd71817e1bb7b4c85593","report_id":"erudio-nct06890598","run_id":"9fcf8500-0f89-409f-b23a-3d2e3e767149","schema_version":"5.0","slug":"sunray-02-nct06890598","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A speaker whose identity and clinical role are not established expresses interest in SUNRAY-02’s treatment timing, without assessing benefit. More detailed commentary concerns LOXO-RAS-20001 and a chemotherapy-containing regimen a medical oncologist judged tolerable and attributed to this trial, although it differs from the protocol. Their broader treatment-selection concerns center on toxicity. The sources reviewed for this edition do not establish trial-specific benefit or safety.","examples":[],"meta_description":"29 sources screened · 42 verified statements (12 from clinicians verified by NPI or staff page) from 8 sources · 4 findings. Updated Nov 22, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-22T00:23:12Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":29},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","24 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 29 sources about other trials or topics are not included.","The cited commentary does not report SUNRAY-02 efficacy or safety outcomes. Its response and toxicity figures concern LOXO-RAS-20001 or other described combinations, and the linked SUNRAY-02 publication describes methods and rationale.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","A speaker’s LinkedIn and X posts repeat the same view. Publication and posting dates do not establish presentation dates, readout timing or changes of opinion.","ClinicalTrials.gov did not list a separate protocol document in the sources reviewed; methods context comes from the protocol publication. No exact olomorasib regulatory label was identified, so this report does not assess labeling or regulatory status."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":0,"publication":1,"registry":0,"regulatory":0,"x_thread":4,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":7,"methods":1},"count":8,"evidence_window":{"end":"2026-11-20","start":"2025-04-16"},"retrieval_snapshot":"2026-11-21T23:09:22.796785Z","timeline":[{"count":1,"week":"2025-W16"},{"count":2,"week":"2025-W48"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W47"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06890598:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06890598:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42823821","quote_policy":"no_derivatives"},{"id":"openfda:9333c79b-d487-4538-a9f0-71b91a02b287:20261016","quote_policy":"short_quote_link_out"},{"id":"openfda:8baba4ea-2855-42fa-9bd9-5a7548d4cec3:20260831","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-cgs6uob26ebv2anhmaesngwk-3msds6wvpcj2c","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7400778141331505152","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7405743583066234880","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915432937970860287:e8c63d53-475f-47d9-afe4-23f8961fc0ae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929544699661938850:ae4ec4a0-c454-4930-8295-60b0dacaf9a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929545106115166666:de44b1b0-f0cd-47fa-9de7-0c5ac8e6bb20","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929545971769266304:e8fc50ee-5282-4a80-8d83-1e47848db5a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938636775666123161:75e500b8-19b2-4fe9-866e-f9b906f221aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964675020640137701:394f6df0-c6cc-42fd-b533-0485fecd4e8e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1965180388118286830:baa0a5e9-6d25-435e-b153-c91ff3905aef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1977731091722117326:b652a872-d56d-483d-9138-27e9317770a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980243211101880447:e7002b8d-61bb-4ab0-8aed-20e66b081943","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1984355427283337615:b6aae6c0-2e94-43db-b45d-7da9fe49bf0e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1995011705659625715:998bd9fe-a074-45aa-907c-b619c4ccf4e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2014729839857586177:b649df71-aadc-417b-92bb-8613c244ca31","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037122392233746446:1254c772-166b-45e7-a0bb-838259e48e20","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037795266527424686:63946514-1ea4-4293-a5e1-0666eef453ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047735193931280875:7dcbb19c-36a8-401a-94b4-4784f755dc6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053099262519447705:5f1da1a8-62fb-4c61-9209-0f4aa8e428eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053391169204232207:a1acba49-d87c-4afc-afab-18d0223ef8cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060762834737520746:08a20bb2-582f-4498-990e-772c1ac22df1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2070486699784728606:268b289e-936b-40e7-a46e-8ba5994ca2c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2075639468753907910:93d87de6-e467-439d-909f-e0028bd13e45","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084988040980684821:1803d19d-3dcc-4351-932f-c001cd9d5d78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103203657781031021:f5cd5523-c2ae-431d-b23e-dca1878ed374","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104586931598131618:fee7d8fd-b708-47b2-98cb-e86371f60448","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2121610108224536622:f9b97e4d-ff8b-42df-8413-92d5c8ade3b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2123913437365535210:2f4eab57-7d19-460b-9389-456a2f55aecf","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:VqKTe-FURD4","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":2,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":25,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":29},"count":29,"evidence_window":{"end":"2026-11-20","start":"2025-04-16"},"retrieval_snapshot":"2026-11-21T23:09:22.796785Z","timeline":[{"count":1,"week":"2025-W16"},{"count":1,"week":"2025-W17"},{"count":3,"week":"2025-W23"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W36"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W44"},{"count":2,"week":"2025-W48"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W04"},{"count":2,"week":"2026-W13"},{"count":1,"week":"2026-W17"},{"count":2,"week":"2026-W19"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W26"},{"count":1,"week":"2026-W28"},{"count":2,"week":"2026-W32"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W46"},{"count":1,"week":"2026-W47"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":3.5,"other":0,"podcast":0,"publication":26,"registry":0,"regulatory":0,"x_thread":6.5,"x_video":0,"youtube":6}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":[{"abstracts":1,"label":"European Lung Cancer Congress 2026","slug":"elcc26","sources":0},{"abstracts":1,"label":"IASLC 2026 World Conference on Lung Cancer","slug":"wclc26","sources":0}],"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"olomorasib","slug":"olomorasib"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Imfinzi"],"label":"durvalumab","slug":"durvalumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"SUNRAY-02","aliases":["SUNRAY-02","Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02"],"brief_title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","collaborators":["AstraZeneca"],"conditions":["Carcinoma, Non-Small-Cell Lung"],"display_condition":"stage II-III KRAS G12C-mutant non-small cell lung cancer","display_interventions":[["olomorasib","pembrolizumab"],["olomorasib","durvalumab"]],"enrollment":{"count":700,"type":"ESTIMATED"},"interventions":[{"name":"Olomorasib","synonyms":["LY3537982"],"type":"DRUG"},{"name":"Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Durvalumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06890598","official_title":"A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2029-05","type":"ESTIMATED"},"primary_endpoints":[{"description":"DFS by Investigator Assessment","measure":"Part A: Disease-Free Survival (DFS) by Investigator Assessment","timeFrame":"Randomization to disease recurrence or death from any cause (Estimated as approximately 4 years)."},{"description":"PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR)","measure":"Part B: Progression-Free Survival (PFS) by BICR","timeFrame":"Randomization to disease progression or death from any cause (Estimated as approximately 3 years)."}],"registered_date":{"date":"2025-03-24","type":"ACTUAL"},"registry_last_updated":"2026-11-04","registry_url":"https://clinicaltrials.gov/study/NCT06890598","short_name":"SUNRAY-02","short_name_basis":"registry_acronym","sponsor":"Eli Lilly and Company","start_date":{"date":"2025-03-27","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"18763","type":"sponsor_study_id"},{"id":"2024-512302-25-00","type":"ctis"},{"domain":"Eli Lilly and Company","id":"J3M-MC-JZQH","type":"other"}],"study_type":"INTERVENTIONAL"}}}